DanCann Pharma A/S: Upcoming legalization in the US and Germany will have a major impact on the acceptance of cannabis worldwide

COPENHAGEN, Denmark, October 11, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby comment on the potential legalization of cannabis in the US and in Germany.

US President Joe Biden has proclaimed that cannabis should no longer be covered by the Narcotics Directive in line with, for example, heroin, and that he would work for increased decriminalization in relation to use and possession. Politicians in Germany, Europe's most populous country, are currently considering a proposal to legalize cannabis for recreational use under pre-defined conditions.

Jeppe Krog Rasmussen, CEO of DanCann Pharma, comments:

- In the cannabis industry, we believe that the new announcements from the US and Germany's upcoming legalization will affect the acceptance of cannabis both in Europe and in the rest of the world. Germany is not only Europe's largest economy, but also the EU's most important "influencer". Legalization there will certainly be of decisive importance.

- It is interesting when Joe Biden wants to decriminalize cannabis under federal auspices in the United States. Many states have already introduced changes in the legislation, and medical cannabis treatment is legal in 37 states. At the same time, we follow developments in Germany with great interest, as our neighbors south of the border are often the forerunners of new initiatives, which are subsequently widely disseminated to the rest of the continent. And it is also a clear expectation that this will happen in the cannabis area, and that Germany can play a decisive role and start a domino effect for the rest of Europe in connection with the legalization of cannabis. We are convinced that the general focus on cannabis will also have a significant effect on the demand for medical cannabis.

Medical cannabis is produced according to standards known from the production of conventional medicines and subject to extensive quality control at the Danish Medicines Agency, although not clinically developed. And for the same reason, medical cannabis in Denmark is referred to as prescription-only, non-registered medicine, which doctors must prescribe in accordance with the Danish Pilot Programme for Medical Cannabis to treat, for example, pain or discomfort in connection with chemotherapy, multiple sclerosis, or other diseases.

But though more people recognize the positive effects that the active ingredients in cannabis can have on various diseases, there are still several problems that need to be dealt with. Among other things, the widespread stigmatization, which for many years has been a heavy burden on the shoulders of the cannabis industry.

Jeppe Krog Rasmussen comments:

- The stigma is still a big challenge, but as more and more studies document the positive effects of the substances, there is a clear movement towards general acceptance by patients, professionals, and NGO’s, who increasingly recognize medical cannabis as a real alternative to traditional and conventional treatment options. We still have a way to go to separate cannabis from abuse, but in that respect, we are assisted by statements from some of the world's most important influencers, such as the President of the United States.

The DanCann Pharma CEO hopes that the increased focus and acceptance of cannabis can contribute to even greater research and demand for treatment options where cannabis can be part of the solution.

Jeppe Krog Rasmussen elaborates:

- All forms of legalization and easing of regulatory conditions, which provide easier access for consumers and patients, help to create a strong incentive for companies in – and close to – the industry. And just in the last year, the manufacturers have noticed a markedly greater interest among the many patients who hope for easier and cheaper access to the products. We therefore need to educate way more doctors, so that they become more confident in offering patients treatment with medical cannabis. We must be better at informing about forms of treatment, effects, and side effects, and we must put effort into this.

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.